A Study of Auxora in Patients With AKI and Injurious Lung Crosstalk - Trial NCT06374797
Access comprehensive clinical trial information for NCT06374797 through Pure Global AI's free database. This Phase 2 trial is sponsored by CalciMedica, Inc. and is currently Not yet recruiting. The study focuses on Acute Kidney Injury. Target enrollment is 150 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
CalciMedica, Inc.
Timeline & Enrollment
Phase 2
May 01, 2024
Aug 01, 2025
Primary Outcome
Days alive, ventilator-free and kidney replacement therapy (KRT)-free from SFISD through Day 30
Summary
Approximately 150 patients with acute kidney injury (AKI) associated with acute hypoxemic
 respiratory failure (AHRF) will be randomized at up to 40 sites. Patients will be randomly
 assigned to either Auxora or matching placebo. Study drug infusions will occur every 24 hours
 for five consecutive days for a total of five infusions.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06374797
Non-Device Trial